Abstracts tagged "Disease Activity"

Abstract Number: 1610 • ACR Convergence 2022
Are Serological Protease-mediated Peptides of Tissue Remodeling and Inflammation the New Disease Activity Biomarkers in Psoriatic Arthritis Patients?
Solveig S. Groen¹, Signe Holm Nielsen², Anne-Christine Bay-Jensen², Mozhgan Rasti³, Darshini Ganatra³, Katerina Oikonomopoulou³ and Vinod Chandran⁴, ¹Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark, ²Nordic Bioscience, Herlev, Denmark, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto, ON, Canada, ⁴Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Inflammatory and degenerative processes in the joint tissues are hallmarks of patients with psoriatic arthritis (PsA). Here, proteases play a major role in remodeling…
Abstract Number: 2032 • ACR Convergence 2022
Major Salivary Gland Ultrasound and Elastography for Assessment of Disease Activity in Patients of Primary Sjögren’s Syndrome
Kunal Chandwar¹, Juhi Dixit¹, Kriti Kishor¹, DOGGA PRASANNA KUMAR², DIGVIJAY EKBOTE³, PUNEET KUMAR¹ and Urmila Dhakad¹, ¹King George's Medical University, Lucknow, India, ²KGMU, LUCKNOW, Uttar Pradesh, India, ³KING GEORGE MEDICAL UNIVERSITY, LUCKNOW, Uttar Pradesh, India
Background/Purpose: To assess major salivary gland involvement by ultrasonography and elastography in patients with Sjögren's syndrome , compare it with controls and correlate the severity…
Abstract Number: 2228 • ACR Convergence 2022
Development of the Takayasu’s Arteritis Integrated Disease Activity Index
Chiara Marvisi¹, Ertugrul Cagri Bolek², Mark Ahlman³, Hugh Alessi⁴, Christopher Redmond⁵, Peter Merkel⁶, Carlo Salvarani⁷, Kaitlin Quinn⁸ and Peter Grayson⁹, ¹Università di Modena e Reggio Emilia and National Institute of Arthritis & Musculoskeletal & Skin Diseases, National Institutes of Health, Bethesda, MD, ²Vasculitis Translational Research Program, NIAMS, NIH, US, Lanham MD, MD, ³National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD, ⁴National Institutes of Health, Bethesda, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Azienda USL -IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Reggio Emilia, Italy, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ⁹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Disease activity indices that accurately assess inflammation in Takayasu's arteritis (TAK) are needed. While clinical assessment is often considered the gold standard, determining if…
Abstract Number: 0306 • ACR Convergence 2022
Maintenance of Disease Activity and Treatment Persistence in Patients with Rheumatoid Arthritis Who Switched from Combination to TNF Inhibitor Monotherapy: Results from the Rheumatology Informatics System for Effectiveness (RISE) Registry
Gabriela Schmajuk¹, Nevin Hammam², Jing Li³, David Collier⁴, Greg Kricorian⁵ and Scott Stryker⁶, ¹UCSF / SFVA, San Francisco, CA, ²Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, PASADENA, CA, ³University of California, San Francisco, San Francisco, CA, ⁴Amgen Inc., Simi Valley, CA, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Amgen Inc., San Francisco, CA
Background/Purpose: Data regarding the maintenance of disease activity (DA) and treatment persistence in patients (pts) who switched from combination therapy to monotherapy for the management…
Abstract Number: 0541 • ACR Convergence 2022
Prevalence of Venous Thrombo-Embolism in Lupus Nephritis and Associated Risk Factors
Tara Tofighi, Jiandong Su and Zahi Touma, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with SLE have an increased risk of developing venous thrombo-embolism (VTE) based on several cohort studies, accounting for significant morbidity and mortality. Lupus…
Abstract Number: 0916 • ACR Convergence 2022
Should RA Patients with Controlled Disease Taper Methotrexate from Targeted Therapy or Continue It? Risk Differences in Sustaining Remission from a Systematic Review and Meta-analysis
Charis Meng, Diviya Rajesh, Bridget Jivanelli, Deanna Jannat-Khah, DrPH, MSPH and Vivian Bykerk, Hospital for Special Surgery, New York, NY
Background/Purpose: Patients with RA often struggle with side effects of methotrexate (MTX). ACR guidelines conditionally recommend the tapering of MTX before tapering biologic (b)DMARDs, but…
Abstract Number: 1339 • ACR Convergence 2022
Impact of the COVID-19 Pandemic on Patients with Rheumatoid Arthritis: Data from the Ontario Best Practices Research Initiative (OBRI)
Matthew Wong-Pack¹, Elliot Hepworth², Mohammad Movahedi³, Bindee Kuriya¹, Janet Pope⁴, Edward Keystone⁵, Carter Thorne⁶, VANDANA AHLUWALIA⁷, Angela Cesta⁸, Carol Mously⁸, Claire Bombardier¹, Arthur Lau⁹ and Sibel Aydin¹⁰, ¹University of Toronto, Toronto, ON, Canada, ²University of Ottawa, Ottawa, ON, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷William Osler Health System, Brampton, ON, Canada, ⁸University Health Network, Toronto, ON, Canada, ⁹McMaster University, Hamilton, ON, Canada, ¹⁰University of Ottawa, Rheumatology, Ottawa, Canada, Ottawa, ON, Canada
Background/Purpose: The COVID-19 Pandemic created challenges for patients with rheumatoid arthritis (RA), including accessing the health care system, transition to unplanned virtual care, reduction in…
Abstract Number: 1495 • ACR Convergence 2022
How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Patients with Ankylosing Spondylitis? – Real World Data from a German Observational Study
Uta Kiltz¹, Jan Brandt-Juergens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵, Christina Budden⁵ and Hans-Peter Tony⁶, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Ambulantes Rheumazentrum, Medizinisches Versorgungszentrum, Erfurt, Germany, ⁴Medizinische Hochschule Hannover, Hannover, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Medizinische Klinik II - Rheumatologie/Immunologie, Universitätsklinikum Würzburg, Würzburg, Germany
Background/Purpose: Obesity is a risk factor for worse overall health in people with ankylosing spondylitis (AS)1. The German non-interventional study AQUILA provides real-world data in…
Abstract Number: 1618 • ACR Convergence 2022
Combined Orbital and Cranial Vessel Wall MRI for Diagnosis and Longitudinal Monitoring of Giant Cell Arteritis
Rennie Rhee, Shubhasree Banerjee, Vatsal Bhatt, Madhura Tamhankar, Quy Cao, Naomi Amudala, Sherry Chou, Morgan Burke, Laurie Loevner, Peter Merkel and Jae Song, University of Pennsylvania, Philadelphia, PA
Background/Purpose: In giant cell arteritis (GCA), there is a critical need to identify patients at risk for vision loss ("ocular GCA"). MRI evaluates neurovascular anatomy…
Abstract Number: 2043 • ACR Convergence 2022
What Does Isolated Anti-Ro52 Antibody Positivity Mean in Sjögren’s Syndrome?
Eléonore Bettacchioli¹, Alain Saraux², Alice Tison³, Divi CORNEC⁴, Maryvonne Dueymes¹, Marta Alarcon-Riquelme⁵ and Valerie Devauchelle⁶, ¹Immunology and Immunotherapy Laboratory, CHRU Brest, Brest, France, ²CHU Brest, Brest, France, ³Rheumatology Department, CHRU Brest, Brest, France, ⁴CHRU Brest, Brest, France, ⁵Center for Genomics and Oncological Research (GENYO), Granada, Spain, ⁶Université de Bretagne Occidentale, Brest, France
Background/Purpose: Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease characterized by a triad of dryness, pain and fatigue in affected patients. Its diagnosis is…
Abstract Number: 2229 • ACR Convergence 2022
Ultrasound Localization Microscopy as a New Tool for Takayasu’s Arteritis Activity Assessment, a Deep Insight Within Carotid Wall Inflammation
Guillaume Goudot¹, Anatole Jimenez², Nassim Mohamedi³, jonas Sitruk³, Lina Khider¹, Hélène Mortelette³, Clément Papadacci², Fabien Hyafil⁴, Mickaël Tanter², Emmanuel Messas¹, Mathieu Pernot² and Tristan Mirault¹, ¹Vascular medicine department, Georges Pompidou European hospital, APHP, Université Paris Cité, INSERM U970 PARCC, Paris, Ile-de-France, France, ²Physics for Medicine Paris, INSERM U1273, ESPCI Paris, CNRS FRE 2031, PSL Research University, Paris, France, ³Vascular medicine department, Georges Pompidou European hospital, APHP, Université Paris Cité, Paris, Ile-de-France, France, ⁴Nuclear medicine department, Georges Pompidou European hospital, APHP, Universite Paris Cite, INSERM U970 PARCC, Paris, Ile-de-France, France
Background/Purpose: Use of sulphur hexafluoride microbubbles (MB) with ultrasound allow to assess arterial wall vascularization through signal enhancement. The use of ultrafast imaging with MB…
Abstract Number: 0331 • ACR Convergence 2022
Anti-dsDNA Antibodies by Multiplex Flow Immunoassay and Critihidia Luciliae Assays in NYU Lupus Registry: Discordance, Association with Nephritis, and Disease Flare Predictive Value
Devyn Zaminski¹, Amit Saxena¹, Peter Izmirly², Jill Buyon² and H Michael Belmont¹, ¹NYU School of Medicine, New York, NY, ²NYU Grossman School of Medicine, New York, NY
Background/Purpose: SLE is characterized by autoantibody production. The most common lupus-specific serology is the anti-dsDNA antibody (anti-DNA). Traditionally, anti-DNA is measured by an enzyme immunoassay…
Abstract Number: 0602 • ACR Convergence 2022
Cellworks Biosimulation Model (CBM) for Rheumatoid Arthritis (RA), Accurately Captures Patient’s Disease Activity at the Molecular Level Using Their Omics Data and Can Bring Personalization to Treatment Selection in RA
Himanshu Grover¹, Ansu Kumar¹, Anushua Chakraborty¹, Susheel George Chandy¹, Vivek Patil¹, Swati Khandelwal¹, Vishwas Joseph¹, Deepak Anil Lala¹, Prashant Ramachandran Nair¹, Karthik Sundara Raju¹, Kunal Ghosh Roy¹, Shahabuddin Usmani¹, Aftab Alam¹, Swaminathan Rajagopalan¹, Yatin Mundkur¹ and Andrew Concoff², ¹Cellworks Group Inc., South San Francisco, CA, ²United Rheumatology, Hauppauge, NY
Background/Purpose: Patients with RA demonstrate varied individual responses to the many treatment options available. In the absence of accurate, precision prediction of medication response, current…
Abstract Number: 0930 • ACR Convergence 2022
Delayed Response to Methotrexate Treatment in Rheumatoid Arthritis Patients Receiving Folic Acid Supplementation
Alberto Sulli, Tamara Vojinovic, Lercara Adriano, Emanuele Gotelli, sabrina Paolino, Alessandri Elisa and Maurizio Cutolo, Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy
Background/Purpose: MTX is the first line conventional synthetic DMARD (csDMARD) for the treatment of rheumatoid arthritis (RA), and folic acid (FA) supplementation is frequently co-prescribed…
Abstract Number: 1355 • ACR Convergence 2022
Relationships Between Work Productivity, Activity Impairment, and Select Patient-Reported Outcomes in Patients with Ankylosing Spondylitis: A Post Hoc Analysis of Two Placebo-Controlled Trials
Marina Magrey¹, James Cheng-Chung WEI², Arne Yndestad³, Andrew Bushmakin⁴, Joseph Cappelleri⁴, Oluwaseyi Dina⁵ and Atul Deodhar⁶, ¹Case Western Reserve University, University Hospitals, Richfield, OH, ²Chung Shan Medical University Hospital, Taichung, Taiwan, ³Pfizer Inc, Oslo, Norway, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Oregon Health & Science University, Portland, OR, USA, Portland, OR
Background/Purpose: Patients (pts) with AS often experience impaired work productivity.1 In pts with AS receiving tofacitinib (oral Janus kinase inhibitor), improvements were observed in work…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].